Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kaopectate Prop 65

This article was originally published in The Tan Sheet

Executive Summary

San Francisco County Judge approves settlement between Pfizer, Attorney General Bill Lockyer in Prop 65 lawsuit regarding Kaopectateanti-diarrheal. Pfizer, which obtained the drug after acquiring Pharmacia, agrees to reformulate Kaopectate liquid with 80% less lead; caplets have not yet been reformulated. "The faster and more extensively Pharmacia removes lead from Kaopectate, the less it will pay in civil penalties," AG's office states June 26. Center for Environmental Health filed suit in 2001 (1"The Tan Sheet" March 26, 2001, p. 21). State AG joined in November 2001...

You may also be interested in...



Smoking Cessation Patch, Gum Prop 65 Warning Federally Preempted - Court

Requiring a special California Proposition 65 pregnancy warning on OTC nicotine-containing smoking cessation patches and gums would conflict with FDA requirements, a San Francisco state court judge has ruled.

Biocon And Mylan's Fulphila And Insulin Plans On Track

Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

Pharma Has High Hopes Of Pilot On Simultaneous Advice From EU Countries

Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers. 

Topics

UsernamePublicRestriction

Register

PS095634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel